Open Access

Effect of hydrothorax EGFR gene mutation and EGFR‑TKI targeted therapy on advanced non‑small cell lung cancer patients

  • Authors:
    • Bo Zhou
    • Jun Nie
    • Weidong Yang
    • Chenhong Huang
    • Ye Huang
    • Hongfei Zhao
  • View Affiliations

  • Published online on: December 31, 2015     https://doi.org/10.3892/ol.2015.4066
  • Pages: 1413-1417
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is a malignancy with the highest incidence of morbidity and mortality worldwide. The lack of effective detection methods leads to the ineffectiveness of convetional therapy. The aim of the current study was to analyze the hydrothorax epidermal growth factor receptor (EGFR) mutation in patients with advanced non‑small lung cancer (NSCLC) and malignant pleural effusion. A new method for clinical treatment was developed through a comparison of the difference of EGFR tyrosine kinase inhibitor (EGFR‑TKI)‑targeted therapy. Between January 2013 and January 2015, 68 cases diagnosed with advanced non‑small lung cancer and malignant pleural effusion, were enrolled in the study. Previous first‑line chemotherapeutic treatment schemes had been unsuccessful. EGFR 19 and EGFR 21 sites were detected for all the patients. Platinum‑based drugs were provided for patients with wild‑type EGFR. These patients served as the control group and underwent four cycles of treatments, with each cycle lasting 3 weeks. TKI medicine Gefitinib (Iressa™) was administered to patients with mutant EGFR tid, po, for a duration of 4‑8 months. These patients served as the experimental group. There were 41 cases of EGFR mutations, of which 13 cases had EGFR 19 site mutations, 16 cases EGFR 21 site mutations, and the remaining 12 cases had 2 site mutations. EGFR mutations were not significant for gender, age, tumor type, stage and diameter (P>0.05). The results showed that the six‑month survival rate, progression‑free survival time (PFS), objective response rate (RP) and disease control rate (DCR) in the experimental group were higher than those in the control group. The drug side‑effects in the experimental group indicated no statistical differences compared to the control group (P>0.05). The incidence of EGFR mutation was higher in patients with advanced non‑small lung cancer and malignant pleural effusion. Targeted therapy improved the survival rate and was deemed to be a safe and effective method for patients with EGFR mutations.
View References

Related Articles

Journal Cover

February-2016
Volume 11 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou B, Nie J, Yang W, Huang C, Huang Y and Zhao H: Effect of hydrothorax EGFR gene mutation and EGFR‑TKI targeted therapy on advanced non‑small cell lung cancer patients. Oncol Lett 11: 1413-1417, 2016
APA
Zhou, B., Nie, J., Yang, W., Huang, C., Huang, Y., & Zhao, H. (2016). Effect of hydrothorax EGFR gene mutation and EGFR‑TKI targeted therapy on advanced non‑small cell lung cancer patients. Oncology Letters, 11, 1413-1417. https://doi.org/10.3892/ol.2015.4066
MLA
Zhou, B., Nie, J., Yang, W., Huang, C., Huang, Y., Zhao, H."Effect of hydrothorax EGFR gene mutation and EGFR‑TKI targeted therapy on advanced non‑small cell lung cancer patients". Oncology Letters 11.2 (2016): 1413-1417.
Chicago
Zhou, B., Nie, J., Yang, W., Huang, C., Huang, Y., Zhao, H."Effect of hydrothorax EGFR gene mutation and EGFR‑TKI targeted therapy on advanced non‑small cell lung cancer patients". Oncology Letters 11, no. 2 (2016): 1413-1417. https://doi.org/10.3892/ol.2015.4066